JNJ icon

Johnson & Johnson

146.36 USD
-2.08
1.40%
At close May 14, 4:00 PM EDT
Pre-market
147.31
+0.95
0.65%
1 day
-1.40%
5 days
-6.07%
1 month
-5.18%
3 months
-6.27%
6 months
-3.63%
Year to date
1.62%
1 year
-3.32%
5 years
-0.87%
10 years
43.73%
 

About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Employees: 139,800

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

151% more first-time investments, than exits

New positions opened: 435 | Existing positions closed: 173

25% more call options, than puts

Call options by funds: $2.64B | Put options by funds: $2.11B

5% more funds holding

Funds holding: 3,832 [Q3] → 4,014 (+182) [Q4]

1.66% more ownership

Funds ownership: 70.16% [Q3] → 71.82% (+1.66%) [Q4]

6% less capital invested

Capital invested by funds: $273B [Q3] → $256B (-$16.5B) [Q4]

23% less funds holding in top 10

Funds holding in top 10: 189 [Q3] → 145 (-44) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 1,330 | Existing positions reduced: 1,910

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$153
5%
upside
Avg. target
$166
14%
upside
High target
$181
24%
upside

7 analyst ratings

positive
43%
neutral
57%
negative
0%
Leerink Partners
David Risinger
40% 1-year accuracy
4 / 10 met price target
5%upside
$153
Market Perform
Downgraded
13 May 2025
Barclays
Matt Miksic
56% 1-year accuracy
22 / 39 met price target
13%upside
$165
Equal-Weight
Maintained
17 Apr 2025
Raymond James
Jayson Bedford
62% 1-year accuracy
18 / 29 met price target
12%upside
$164
Outperform
Maintained
16 Apr 2025
Morgan Stanley
Terence Flynn
36% 1-year accuracy
8 / 22 met price target
15%upside
$169
Equal-Weight
Maintained
16 Apr 2025
RBC Capital
Shagun Singh
48% 1-year accuracy
33 / 69 met price target
24%upside
$181
Outperform
Reiterated
16 Apr 2025

Financial journalist opinion

Based on 106 articles about JNJ published over the past 30 days

Positive
CNBC Television
13 hours ago
Jim Cramer talks good companies getting pummeled by rising interest rates
'Mad Money' host Jim Cramer talks opportunity stocks as rising interest rates weigh on some equities.
Jim Cramer talks good companies getting pummeled by rising interest rates
Neutral
Business Wire
16 hours ago
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast.
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Positive
The Motley Fool
1 day ago
The Smartest Dividend Stocks to Buy With $5,000 Right Now
If you have some spare cash, it's a great idea to put it into some dividend-paying stocks. They're a useful source of passive income that can help supplement your earned income.
The Smartest Dividend Stocks to Buy With $5,000 Right Now
Neutral
Seeking Alpha
1 day ago
Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Tim Anderson - Bank of America Tim Anderson I think we're live. Thank you for joining us.
Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript
Negative
Barrons
1 day ago
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
Positive
Seeking Alpha
2 days ago
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies, including Pfizer and Nordstrom, met the "safer" qualification with free cash flow yields exceeding dividend yields. Analysts estimate net gains of 19.58% to 41.46% for top Fortune 50 WMA companies by May 2026, with Novo Nordisk leading.
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Neutral
CNBC
2 days ago
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality.  Trump signed a sweeping executive order directing several federal agencies to renew that effort, called the "most favored nation" policy.
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
Negative
Seeking Alpha
2 days ago
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specific breakdown of the trade between these two countries and JNJ's relatively minor exposure to China.
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
Neutral
Market Watch
2 days ago
10 stocks for a high-tariff world
Low-volatility stocks may be your best bet for the next several years.
10 stocks for a high-tariff world
Positive
WSJ
2 days ago
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Drugmakers are spared worst-case drug pricing scenario for now
Charts implemented using Lightweight Charts™